Format

Send to

Choose Destination
Exp Gerontol. 2015 Aug;68:51-8. doi: 10.1016/j.exger.2014.12.002. Epub 2014 Dec 3.

How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story.

Author information

1
Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, Oklahoma City VA Medical Center, Oklahoma City, OK 73104, USA. Electronic address: Arlan-richardson@ouhsc.edu.
2
Department of Physiology and Barshop Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78245, USA.
3
Sanders-Brown Center on Aging, Department of Pharmacology & Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA.
4
Banner Sun Health Research Institute, Sun City, AZ 85351, USA; Department of Basic Medical Sciences, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.

Abstract

The discovery that rapamycin increases lifespan in mice and restores/delays many aging phenotypes has led to the speculation that rapamycin has 'anti-aging' properties. The major question discussed in this review is whether a manipulation that has anti-aging properties can alter the onset and/or progression of Alzheimer's disease, a disease in which age is the major risk factor. Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer's disease (AD-Tg) as well as reduce Aβ and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation. All of these parameters are widely recognized as symptoms central to the development of AD. Furthermore, rapamycin has also been shown to improve memory and reduce anxiety and depression in several other mouse models that show cognitive deficits as well as in 'normal' mice. The current research shows the feasibility of using pharmacological agents that increase lifespan, such as those identified by the National Institute on Aging Intervention Testing Program, to treat Alzheimer's disease.

KEYWORDS:

Alzheimer's disease; Behavior; Cognition; Rapamycin

PMID:
25481271
DOI:
10.1016/j.exger.2014.12.002
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center